Recognise the wider value of diagnostics, says BIVDA (British In Vitro Diagnostics Association)
This article was originally published in Clinica
Executive Summary
"Recognise the enormous input of laboratory medicine beyond simply diagnosing illness" - this was the message issued last week by the British In Vitro Diagnostics Association (BIVDA), in response to a government report that stresses the importance precisely of shifting the focus of the healthcare industry from tackling disease to preventing it.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.